AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Immune system disorder

psoriasis

An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.

🔔 Follow weekly
🧬7244genes / proteins with evidence
💊194drugs and clinical candidates
🧪12+recruiting trials worldwide
✅46approved
📈16phase 3
🛡️

Understand psoriasis

Autoimmune diseases · The immune system attacking the body
🎓 Learn more

What it is

A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast.

Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope.

Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include:

From MedlinePlus: Psoriasis (US National Library of Medicine) ↗

🛡️ Autoimmune diseases: In autoimmune diseases the immune system, which should fight germs, attacks the body's own healthy tissue - the joints in rheumatoid arthritis, many organs in lupus, nerves in multiple sclerosis.

❓ Why it happens

  • A mix of genes and triggers - such as infections, smoking or hormones - but the exact cause is often unknown.
  • They are more common in women.

🫀 What it does to the body

  • Long-lasting inflammation causes pain, swelling and tiredness, and can damage joints and organs.

🧱 Why it is hard to cure

  • Calming the immune system too much makes infections more likely.
  • Flare-ups are hard to predict, and most of these diseases can be controlled but not yet cured.

🚀 What research is trying now

  • Targeted medicines (biologics, JAK inhibitors) that block single steps of inflammation.
  • CAR-T cell therapy that "resets" the immune system, showing early promise in severe lupus.
  • Therapies that teach the immune system to tolerate the body again.

General information about autoimmune diseases, reviewed by people; it does not describe any one person. Below: the evidence for psoriasis itself.

🤖

AI briefing

Where the science on psoriasis stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens psoriasis.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
CARD14 caspase recruitment domain family member 14PROTAC🧊 AlphaFold structure ↗ 0.84
IL36RN interleukin 36 receptor antagonistantibody🧊 AlphaFold structure ↗ 0.82
IL12B interleukin 12Bantibodysmall molecule🧊 AlphaFold structure ↗ 0.80
TYK2 tyrosine kinase 2PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.75
TRAF3IP2 TRAF3 interacting protein 2small molecule🧊 AlphaFold structure ↗ 0.69
IL17RA interleukin 17 receptor APROTACantibody🧊 AlphaFold structure ↗ 0.68
IL23A interleukin 23 subunit alphaantibodysmall molecule🧊 AlphaFold structure ↗ 0.68
PDE4A phosphodiesterase 4APROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.66
AP1S3 adaptor related protein complex 1 subunit sigma 3PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.66
TNF tumor necrosis factorPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.64
IL17A interleukin 17APROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.64
VDR vitamin D receptorPROTACsmall molecule🧊 AlphaFold structure ↗ 0.64
AHR aryl hydrocarbon receptorPROTACsmall molecule🧊 AlphaFold structure ↗ 0.63
ITGB2 integrin subunit beta 2PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.62
NR3C1 nuclear receptor subfamily 3 group C member 1PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.61

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to psoriasis, by how far it has got
Approved · 20
AcitretinRetinoid receptor agonistApproved
AdalimumabTNF-alpha inhibitorApproved
AnthralinApproved
ApremilastPhosphodiesterase 4 inhibitorApproved
BergaptenApproved
Betamethasone DipropionateGlucocorticoid receptor agonistApproved
Show all 20
BimekizumabInterleukin 17A inhibitor; Interleukin-17F inhibitorApproved
BrodalumabInterleukin-17 receptor A antagonistApproved
CalcipotrieneVitamin D receptor agonistApproved
CalcitriolVitamin D receptor agonistApproved
Clobetasol PropionateGlucocorticoid receptor agonistApproved
Coal TarApproved
CyclosporineCyclophilin A modulatorApproved
DesoximetasoneGlucocorticoid receptor agonistApproved
DeucravacitinibTyrosine-protein kinase TYK2 negative allosteric modulatorApproved
DexamethasoneGlucocorticoid receptor agonistApproved
Dexamethasone Sodium PhosphateGlucocorticoid receptor agonistApproved
Dimethyl FumarateKelch-like ECH-associated protein 1 inhibitorApproved
EfalizumabIntegrin alpha-L/beta-2 (LFA-1) inhibitorApproved
EtanerceptTNF-alpha inhibitorApproved
In phase 2 / 3 · 20
AtorvastatinHMG-CoA reductase inhibitorPhase 3
BetamethasoneGlucocorticoid receptor agonistPhase 3
Betamethasone ValerateGlucocorticoid receptor agonistPhase 3
BriakinumabInterleukin-23 inhibitor; Interleukin-12 inhibitorPhase 3
Certolizumab PegolTNF-alpha inhibitorPhase 3
Halobetasol PropionateGlucocorticoid receptor agonistPhase 3
Show all 20
Mometasone FuroateGlucocorticoid receptor agonistPhase 3
PefcalcitolVitamin D receptor agonistPhase 3
PiclidenosonAdenosine A3 receptor agonistPhase 3
Prednisolone AcetateGlucocorticoid receptor agonistPhase 3
SemaglutideGlucagon-like peptide 1 receptor agonistPhase 3
TacrolimusFK506-binding protein 1A inhibitorPhase 3
Tacrolimus AnhydrousFK506-binding protein 1A inhibitorPhase 3
TofacitinibJanus Kinase (JAK) inhibitorPhase 3
VehiclePhase 3
ZasocitinibPhase 3
NiacinamidePhase 2/3
Abacavir HydroxyacetatePhase 2
AbrocitinibTyrosine-protein kinase JAK1 inhibitorPhase 2
AdriforantHistamine H4 receptor antagonistPhase 2
Early trials · 20
Bfh-772Vascular endothelial growth factor receptor 2 inhibitorPhase 1/2
Bms-986251Phase 1/2
Folic AcidPhase 1/2
OchromycinonePhase 1/2
Parathyroid HormoneParathyroid hormone receptor agonistPhase 1/2
PyridoxinePhase 1/2
Show all 20
TeplizumabT-cell surface glycoprotein CD3 epsilon chain otherPhase 1/2
VimirogantPhase 1/2
Vitamin B12Phase 1/2
Amg-557ICOS ligand inhibitorPhase 1
Amg-811Interferon gamma inhibitorPhase 1
Bms-986202Phase 1
BrazikumabInterleukin-23 inhibitorPhase 1
BrepocitinibTyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK1 inhibitorPhase 1
Cjm-112Interleukin 17A binding agentPhase 1
DalazatidePhase 1
ErgocalciferolVitamin D receptor agonistPhase 1
FezakinumabInterleukin-22 inhibitorPhase 1
FletikumabInterleukin-20 inhibitorPhase 1
Glpg-3970Phase 1
🧪

Recruiting trials

Worldwide, open to new patients now
Molecular Inflammation Board at the Center for Personalized MedicineNCT07132333 · n/a · 📍 TübingenCarotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic D…NCT07611747 · Phase 4 · 📍 AlicanteTreatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselk…NCT07166315 · n/a · 📍 BathStudy of S-4321 in Participants With an Autoimmune or Immune-mediated DiseaseNCT07455578 · Phase 1 · 📍 CharlestownA Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)NCT06029257 · n/a · 📍 GrazThe Effect of Anti-IL17 on Airway Hyperresponsiveness and ResistanceNCT06224634 · n/a · 📍 HvidovreStudy to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab E…NCT04846959 · n/a · 📍 MorrisvilleStudy to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Se…NCT07039110 · n/a · 📍 CalgaryEvaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118NCT06846710 · Phase 1 · 📍 AnaheimEffect of Addition of Pyramidal Exercise to Intermittent Fasting on Dryness of Eye in Pre-diabetic Psoriasis …NCT06893913 · NA · 📍 GizaDisease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and PsoriasisNCT03361215 · n/a · 📍 KielObservational Study of Pediatric Rheumatic Diseases: The CARRA RegistryNCT02418442 · n/a · 📍 Birmingham Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy